Abstract: Recent studies implied that low-density lipoprotein (LDL) modified predominantly by oxidation or glycation, significantly contributes to the formation of atherosclerotic lesions. In contrast to oxidized LDL (ox-LDL), high-density lipoprotein (HDL) is able to prevent accumulation of ox-LDL in arterial walls. This antiatherogenic property of HDL is attributed in part to several enzymes associated with the lipoprotein, including HDL-associated paraoxonase 1 (PON1). In this study we analyzed PON1 arylesterase/paraoxonase activities in relation to serum lipid profile, gender and age in thirty clinically healthy Slovak volunteers. Our results showed that PON1 arylesterase and paraoxonase activities were lower in citrated plasma than in serum by 16.6% and 27.3%, respectively. Among serum lipoproteins, only HDL-cholesterol level showed significant positive correlation with PON1 arylesterase activity (p = 0.042). Likewise, we found a significant relationship between atherogenic index (AI = total cholesterol/HDL-cholesterol) and PON1 arylesterase activity (p = 0.023). No significant correlation could be demonstrated between PON1 paraoxonase activity and serum lipid profile, age or gender. Furthermore, it was found that PON1 paraoxonase/arylesterase activities were higher in women compared with both investigated activities in men, but these differences were not statistically significant. These results confirmed a positive correlation between HDL-cholesterol and PON1 arylesterase activity. Moreover, it was found out that PON1 paraoxonase activity is not influenced either by gender or by age. PON1 arylesterase activity was however affected by gender to a limited extent.
Introduction
In the past decade a number of studies suggested that antiatherogenic properties of high-density lipoproteins (HDL) may be due to several enzymes with antioxidant properties, such as platelet-activating factor acetylhydrolase or paraoxonase 1 (PON1) (Libby, 2001) .
PON1 is a protein with a molecular weight of about of 43,000 Da. It is synthesized in the liver and secreted into the serum (Teiber et al., 2003) but it was detected also in other tissues, such as kidney or intestine. The gene for this human protein is situated on chromosome 7 and it shows several polymorphisms influencing both PON1 activity and concentration. Apart from the ability to metabolize toxic synthetic neurotoxin-paraoxon, lactons and other compounds such as phenyl acetate, PON1 can protect lipoprotein particles (mainly lowdensity lipoprotein; LDL) from free-radical-induced oxidative modification. It is able to inhibit lipoprotein oxidation by hydrolyzing lipid peroxides, such as specific oxidized cholesteryl esters and phospholipids (Navab et al., 1996; Aviram et al., 1998 Aviram et al., , 2000 Aviram, 1999; Aviram & Rosenblat, 2004) , and it thus may reduce initiation as well as progression of inflammatory processes in the artery walls.
Many human and animal studies have already pointed out an association between decreased or lacking PON1 activity and the incidence as well as the 700 K. Sumegová et al.
severity of atheroslerosis or other cardiovascular diseases (Abbott et al., 1995; Shih et al., 1998; James et al., 2000; . However, the exact mechanisms responsible for PON1 effect remain so far unknown.
The results of studies are also controversial relative to the positive correlation between PON1 activity and HDL-cholesterol concentrations or the negative correlation between PON1 and LDL-cholesterol. Several reports have shown that PON1 activity correlates with this traditional risk factor of atherosclerosis, while others did not find any significant association. Moreover, there is still requirement for validity of existing range of reference values of PON1 activities among humans, because various values of PON1 activities were determined in different countries (Durrington et al., 2001 ). This variability of PON1 activities may stem from different lifestyle and dietary habits, as well as from using different investigative methods.
The aims of this pilot study were as follows: (1) to compare the activities of PON1 in serum and in citrated plasma in healthy volunteers from the methodological point of view; (2) to determine PON1 paraoxonase and PON1 arylesterase activities in 30 Slovak healthy subjects and thus to contribute to validity of existing data; and (3) to investigate the correlations between both activities and variables of lipid profile, gender or age.
Material and methods
Subjects and blood sample preparation Thirty volunteers, aged between 21 and 73 years (mean age 41.3 ± 2.9), were included in this study after their written consent. None of them suffered from diabetes mellitus, acute cardiovascular disease or chronic inflammation disease. Four subjects were active or occasional smokers.
Blood samples were collected into vacutainer tubes with and without anticoagulant (citrate). Citrated plasma and serum were separated by centrifugation at 1,200 × g for 10 min. All samples were frozen immediately after centrifugation and kept at −80
Determination of lipid profile Serum total-cholesterol, HDL-cholesterol and triacylglycerols (TAG) were determined by routine laboratory analyses. LDL was calculated according to Friedewald's formula (FRIEDEWALD et al., 1972) .
Determination of PON1 arylesterase activity PON1 arylesterase activity in citrated plasma or serum was determined spectrophotometrically (Biochrom 4060, Cambridge, UK) by using phenyl acetate (Sigma, USA) as substrate according to GAN et al. (1991) . Briefly, after addition of 100 µL of substrate solution (10 mM), prepared daily before the beginning of each assay, to a reaction mixture containing 5 µL biological material (citrated plasma or serum) and 1 mM CaCl2 (Sigma, USA) in 50 mM Tris-HCl buffer, pH 8 (Fluka Chemie, Switzerland), production of phenol was detected after 2 min at 270 nm. The molar extinction coefficient 1,310 mol −1 · L · cm −1 was used for the expressing of enzyme activity. PON1 arylesterase activity was determined in triplicate and all results are presented in µmol of phenol produced per min per mL of serum or citrated plasma. Mean intra-assay and inter-assay coefficients of variation for this analysis were lower than 4.2% and 7.1%, respectively.
Determination of PON1 paraoxonase activity PON1 paraoxonase activity in citrated plasma or serum was determined spectrophotometrically at 412 nm according to BELTOWSKI et al. (2002) with some modifications. The reaction was initiated by adding commercial paraoxon (Sigma, USA) purified by chloroform and isoamylalcohol before using (3.3 mM) as a substrate to assay mixture containing 10 µL serum or citrated plasma and 1 mM CaCl2 (Sigma, USA) in 20 mM Tris-HCl buffer, pH 8 (Fluka Chemie, Switzerland). The production of p-nitrophenol was detected after 3 minutes. The molar extinction coefficient for p-nitrophenol was 18,290 mol −1 · L · cm −1 and one unit of paraoxonase activity per milliliter of sample corresponded to the production of 1 nmol of produced p-nitrophenol per minute under above defined conditions. PON1 paraoxonase activity was monitored in triplicate and all results are presented in nmol per min per mL. Mean intra-assay and inter-assay coefficients of variation were lower than 13.5% and 11%, respectively.
Statistical analysis
All results are presented as mean ± standard error of the mean (SEM). Student's unpaired t-test was used for the analysis of experimental data with a gausian distribution. The data with nongausian distribution were compared by Mann-Whitney U-test. P-value of less than 0.05 was considered statistically significant. The Pearson's and Spearman's correlation coefficients were used to determine the strength of the association between two analyzed parameters. Statistic analyses were performed by using StatsDirect (Stats Direct Sales, Sale, Cheshire M33 3UY, UK).
Results
Personal and biochemical characteristics of volunteers are shown in Table 1 .
PON1 arylesterase/paraoxonase activities PON1 activity was measured both in serum and citrated plasma of study subjects. PON1 arylesterase activity in citrated plasma was by 16.6% (71.7 ± 2.4 µmol/min/mL; n = 28; range: 51.6-100.3 µmol/min/ mL) lower than in serum (86.0 ± 3.3 µmol/min/mL; n = 30; range: 49.8-121.0 µmol/min/mL). PON1 paraoxonase activity in citrated plasma was 72.7% (68.3 ± 11.0 nmol/min/mL; n = 27; range: 4.8-181.3 nmol/min/mL) of that found in serum (93.8 ± 14.4 nmol/min/mL; n = 30; range: 10.6-287.9 nmol/min/mL). There was a great variability in PON1 paraoxonase activities between individuals included in this study. The degree of agreement between PON1 arylesterase/paraoxonase activities determined in serum and citrated plasma samples is presented in Figure 1 . The mean bias for PON1 arylesterase activity was −16.6 µmol/min/mL (Fig. 1A) , whereas for PON1 (21) 6.4 ± 0.5 (9) 0.003** Serum PON1 arylesterase activity (µmol/min/mL) 86.0 ± 3.3 (30) 90.1 ± 3.5 (21) 76.6 ± 6.3 (9) 0.056 Serum PON1 paraoxonase activity (nmol/min/mL) 93. 8 ± 14.4 (30) 97.8 ± 17.9 (21) 84.6 ± 24.4 (9) 0.594 a Data are expressed as mean ± SEM, n means the number of subjects in our study group; AI (atherogenic index) = total cholesterol/HDL-cholesterol; P means significant difference between females and males; ** P < 0.01, *** P < 0.001. paraoxonase activity −24.5 nmol/min/mL (Fig. 1B) . The correlation coefficients between serum and citrated plasma samples were r = 0.803 and r = 0.966 for PON1 arylesterase and PON1 paraoxonase activities, respectively.
Serum PON1 activity and its relationships to lipid variables and age
The relationships between serum PON1 arylesterase or paraoxonase activities and characteristics of lipid profile were studied. As shown in Table 2 , both activities did not correlate with levels of calculated LDLcholesterol, or total-cholesterol. PON1 arylesterase activity significantly correlated with HDL-cholesterol (r = 0.374, p = 0.042) and atherogenic index (AI = total cholesterol/HDL-cholesterol) (r = −0.412, p = 0.023), whereas no such significant associations were found for PON1 paraoxonase activity. Furthermore, both serum activities were inversely related to age but these associations did not reach the levels of significance (r = −0.220, p = 0.241 for PON1 arylesterase activity and r = −0.291, p = 0.118 for PON1 paraoxonase activity). Table 1 shows PON1 arylesterase and PON1 paraoxonase activities and the lipid profile of subjects correlated to gender. PON1 arylesterase activity was marginally affected by gender. Females showed a tendency to higher PON1 arylesterase activity than males (p = 0.056). PON1 paraoxonase activity in men was by 
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Bland-Altman plots for (A) PON1 arylesterase activity (µmol/min/mL) and (B) PON1 paraoxonase activity (nmol/min/mL) determined in serum and citrated plasma. a Data are expressed as mean ± SEM, n means the number of subjects in our study group; AI (atherogenic index) = total cholesterol/HDL-cholesterol; *P < 0.05, *** P < 0.001.
13.5% lower compared to females; however, this difference was not significant (p = 0.594). HDL-cholesterol levels were also significantly lower in men than in females by 28.6% (p = 0.0004). Conversely, TAG levels and AI were significantly higher in males than in females (p = 0.006 and p = 0.003, respectively). Furthermore, there were slightly higher levels of total-and LDL-cholesterol in men when compared to women, but these differences were not statistically significant (p = 0.497 for total cholesterol and p = 0.366 for LDL-cholesterol).
PON1 activities in normo-and hyper-cholesterolemic individuals PON1 activities in serum samples obtained from 13 normocholesterolemic control subjects and 17 hypercholesterolemic individuals were compared. General and biochemical variables of control and hypercholesterolemic individuals are shown in Table 3 . The level of total cholesterol above 5.17 mM (according to our laboratory reference values) was the inclusion criterion for hypercholesterolemic subjects.
PON1 arylesterase activity ranged from 58.7 to 121.0 µmol/min/mL in hypercholesterolemics while from 49.8 to 115.6 µmol/min/mL in the control normocholesterolemic group. There was found no significant difference between activities of controls and hypercholesterolemic subjects (p = 0.584).
PON1 paraoxonase activities were also similar in both groups and there was observed no significant difference (p = 0.804). Hypercholesterolemic individuals had PON1 paraoxonase activity ranging between 10.6 and 232.0 nmol/min/mL while in controls this activity was between 10.9 and 204.1 nmol/min/mL.
Discussion
Healthy populations in different countries have different PON1 activity (Durrington et al., 2001 ) and also there is no range of reference values for PON1. For this reason we determined PON1 paraoxonase and PON1 arylesterase activities in healthy subjects both in serum and citrated plasma samples. Furthermore, methodically we wanted to check out accuracy of determination of PON1 activities and possible differences in activity determination in serum and citrated plasma. Because the physiological substrate of PON1 is still unknown, two synthetic compounds, paraoxon and phenyl acetate, have been used as substrates for analysis of catalytic activities of PON1 enzyme in this study. Beltowski et al. (2002) found that PON1 activity towards phenyl acetate, as well as towards paraoxon is lower in heparinised plasma than in serum (for PON1 arylesterase activity by median 12.8% and for PON1 paraoxonase activity by median 12.2%). In the case of EDTA plasma samples Mackness (1998) reported that PON1 activity towards paraoxon showed 88% inhibition. In this study we found out decrease of PON1 arylesterase activity by 16.6% and PON1 paraoxonase activity by 27.3% in citrated plasma in comparison to serum values. Therefore citrate seems to be much less potent inhibitor of PON1 activity compared with EDTA. Durrington et al. (2001) stated that serum PON1 activity is associated with HDL-cholesterol. Nevin et al. (1996) showed that PON1 arylesterase activity positively correlated with HDL-cholesterol. Lee et al. (2004) reported that PON1 arylesterase activity was significantly associated with HDL-cholesterol in Greek subjects but in Anglo-Celtic subjects they observed no significant correlation. Therefore, we could contribute to investigating these associations. We found out, in agreement with the above-mentioned authors, that PON1 arylesterase activity positively correlates with HDL-cholesterol in healthy subjects. Compared with other lipid variables, there was no relationship between PON1 arylesterase activity and total cholesterol, LDL-cholesterol or TAG (Table 2) .
On the other hand, PON1 paraoxonase activity did not show any correlation with variables of lipid profile (Table 2) , though Mackness et al. (2000) reported that PON1 paraoxonase activity in healthy subjects from Belfast was associated with total-and HDL-cholesterol. The explanation for the lack of correlations between PON1 paraoxonase activity and lipid profile characteristics could result from either great variability of PON1 paraoxonase activity among individuals, as a consequence of several polymorphisms in the coding regions of PON1 gene, or from the fact, that paraoxon is rather a substrate for monitoring the hydrolytic activity of PON1 against exogenous toxic metabolites than for assessment of antioxidant activity related to the inhibition of oxidative modification of lipids. Mackness et al. (1998) asserts that no differences between genders in PON1 activity have been reported, though there is a distinction in the concentrations of HDL-cholesterol between females and males. Tomás et al. (2000) presented very similar PON1 arylesterase activities between control normolipidemic men and women. In the present study we demonstrate a border difference (p = 0.056) in PON1 arylesterase activities between both genders (Table 1) . Therefore, this finding needs further studies. Our finding concerning the PON1 paraoxonase activity is in accordance with the conclusion of Mackness et al. (1998) quoted above.
According to our results PON1 arylesterase/paraoxonase activities were not significantly different in hypercholesterolemic and control patients (Table 3) . This finding is in contrast to the assertion that high serum cholesterol is associated with decreased PON1 activity (Mackness et al., 1991 . Probably a larger number of volunteers with higher totalcholesterol level is needed to confirm a significant difference.
Based on our results, we can conclude that: (1) determination of PON1 activities in serum and citrated plasma could be interchangeable for lower values in order to compare independent results but it cannot be changeable within one project (for higher values there is questioning); (2) serum PON1 arylesterase activity correlates with HDL-cholesterol and AI in clinically healthy subjects; (3) both, PON1 paraoxonase and arylesterase activities are not dependent on age, TAG, level of total-and LDL-cholesterol; and (4) PON1 arylesterase activity may exhibit a tendency to be higher in women in comparison to men.
